Chester County News and Community Website
RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) announced that new data from its Phase 2 Explore-CKD trial evaluating lorundrostat in patients with hypertension and chronic kidney disease (CKD) will …
Mineralys Therapeutics to Present Key Lorundrostat Data at ASN Kidney Week 2025 Read More RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) announced it has completed enrollment in its Phase 2 EXPLORE-OSA trial evaluating lorundrostat in patients with moderate-to-severe obstructive sleep apnea (OSA) and …
Mineralys Completes Enrollment in Phase 2 Sleep Apnea and Hypertension Trial Read More RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) announced new subgroup analyses from its Phase 3 Launch-HTN trial, showing that its investigational therapy lorundrostat significantly lowered blood pressure across multiple …
Mineralys Reports Strong Phase 3 Results for Lorundrostat in High-Risk Hypertension Patients Read More RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) reported a series of positive clinical milestones and second-quarter 2025 financial results, positioning its lead drug candidate, lorundrostat, for a potential new …
Mineralys Therapeutics Advances Hypertension Drug Toward FDA Filing After Strong Clinical Results Read More RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) has announced the publication of groundbreaking results from its pivotal Phase 3 Launch-HTN trial in the Journal of the American Medical Association …
Mineralys Therapeutics Publishes Phase 3 Trial Results in JAMA for Hypertension Treatment Read More RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) announced promising topline results from its Phase 2 Explore-CKD trial, evaluating lorundrostat as a treatment for hypertension in patients with chronic kidney …
Mineralys Therapeutics Reports Positive Phase 2 Trial Results for Lorundrostat in Hypertension and CKD Read More RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) has announced detailed results from its pivotal Phase 3 Launch-HTN trial, showcasing the efficacy and safety of lorundrostat for patients with uncontrolled …
Mineralys Therapeutics Reveals Promising Phase 3 Results for Hypertension Drug Lorundrostat Read More RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) has announced that the findings from its pivotal Phase 3 Launch-HTN trial on lorundrostat, a novel medication targeting uncontrolled hypertension (uHTN) and …
Mineralys Therapeutics to Present Phase 3 Data on Lorundrostat at European Hypertension Meeting Read More RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) has reported its financial results for the first quarter ended March 31, 2025, alongside major updates on its pivotal clinical trials and …
Mineralys Therapeutics Announces Q1 2025 Financial Results and Achievements Read More RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) has announced that its management team will participate in the prestigious Bank of America Securities 2025 Health Care Conference. The event, which …
Mineralys Therapeutics to Present at Bank of America Health Care Conference Read More